Young
|
2015
|
Multi-center double-blind, cluster randomized, double-crossover trial
|
90 days after randomizations for all variables
|
Hospital and ICU mortality, AKI and RRT
|
Plasma-Lyte
|
1152
|
Saline
|
1110
|
Verma
|
2016
|
Multi-center double-bind randomized controlled trial
|
AKI during the first 4 days while other outcomes till discharge
|
Hospital and ICU mortality, AKI and RRT
|
Plasma-Lyte
|
33
|
Saline
|
34
|
Semler (SMART trial)
|
2018
|
Single center unblinded, cluster randomized, multiple crossover trial
|
Death at 60 days, AKI after enrollment, RRT at 28 days.
|
Hospital and ICU mortality, AKI and RRT
|
LR or Plasma-Lyte
|
7942
|
Saline
|
7860
|
Semler (SALT trial)
|
2016
|
Single-center prospective, open-label, cluster-randomized, multiple crossover trial
|
Death at 60 days, AKI after enrollment, RRT at 28 days.
|
Hospital and ICU mortality, AKI and RRT
|
LR or Plasma-Lyte
|
520
|
Saline
|
454
|
Young
|
2014
|
Single center randomized, double-blind, parallel-group clinical trial
|
In-hospital mortality at 30 days
|
Hospital mortality
|
Plasma-Lyte
|
22
|
Saline
|
24
|
Ratanarat
|
2017
|
Single-center randomized controlled trial
|
AKI during the first 7 days
|
AKI and RRT
|
Balanced
|
88
|
Saline
|
93
|